Reducing Complement Inhibition to Treat Leukemia and Lymphoma

描述(由申请人提供)：申请的资金将产生一种新的白血病和淋巴瘤联合癌症疗法的安全性和有效性数据。单抗是一类新兴的肿瘤治疗药物。我们正在开发一种分子，可以通过以下方式提高mAbs的治疗效果：1)提高癌症对治疗的敏感性；2)揭开耐药癌症，使它们再次变得敏感；3)有可能治疗已经变得难以治疗的癌症。该项目将推动临床候选药物在未来的人体试验中取得进展。MAb治疗的剂量节约和成本降低、癌症预后的改善以及为先前耐药的癌症提供新的治疗方法的公共健康影响是重要的。这项研究的直接目标是收集数据，以便能够提交淋巴瘤联合疗法的研究新药(IND)。我们在华盛顿大学的顾问收集了大量信息，支持去除细胞表面CD46与抗体治疗相结合治疗血癌的优越性。我们的长期目标是将这项技术从研究平台转化到临床床边，从而加强单抗(MAb)治疗。 公共卫生相关性：虽然单抗治疗可以是治疗癌症的有效方法，但需要进一步的进展才能增加治疗的成功率。我们打算加强癌症治疗，以改善全球的治疗。

DESCRIPTION (provided by applicant): The funding of the application will yield safety and efficacy data on a new combination cancer therapy for leukemia and lymphomas. Monoclonal antibodies (mAbs) have emerged as a class of novel oncology therapeutics. We are developing a molecule that can improve the therapeutic effects of mAbs by: 1) increasing the sensitivity of cancers to treatment 2) unmasking resistant cancers so they again become sensitized and 3) potentially allowing treatment of cancers that have become refractory to therapy. This project will move a clinical candidate forward for future testing in humans. The public health implications of dose-sparing and cost reduction for mAb therapy, improved outcomes in cancer and making a new therapy available for previously resistant cancers are significant. The immediate goal of the research is to collect data to enable an Investigational New Drug (IND) filing on a combination therapy for lymphoma. Our consultant at the University of Washington has collected a significant body of information supporting the superiority of the combination of depleting CD46 on the cell surface with antibody therapy in blood cancers Our long-term goal is to translate the technology from research bench to clinical bedside leading to enhancement of monoclonal antibody (mAb) therapy. PUBLIC HEALTH RELEVANCE: Although monoclonal antibody therapy can be an effective way to treat cancer, further progress is needed to increase therapeutic success. We intend to enhance cancer therapy to improve treatment worldwide.